MYO•MYO•The company raised full-year 2026 revenue guidance to $45 million to $47 million and said it expects cash burn to be less than $2 million in the second half of 2026.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Loss Per Share | $0.09 | ||
| Q2 Net Loss | $4.02 mln | ||
| Q2 Adjusted EBITDA | Beat | -$827,282 | -$3.16 mln (3 Analysts) |
| Q2 Operating Expenses | $10.70 mln |
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
Wall Street's median 12-month price target for Myomo Inc is $3.00, about 177.8% above its August 4 closing price of $1.08.
Myomo reported a narrower adjusted EBITDA loss in the second quarter that beat analyst expectations, while revenue rose 21% year over year on higher average selling price and unit sales.
The company said 53% of Q2 revenue came from recurring sources like provider referrals, O&P partners, and the VA, up from 26% a year ago. Revenue growth also reflected a higher average selling price and a 19% increase in MyoPro units recognized as revenue.
Gross margin improvement was driven by higher ASP and cost reductions, including the rollout of the Myomo Mobile App, partially offset by higher clinical costs.
